Pamidronate for Pain Relief in Prostate Cancer
Author Information
Author(s): N.W. Clarke, I.B. Holbrook, J. McClure, N.J.R. George
Primary Institution: University Hospital, South Manchester
Hypothesis
Can Pamidronate effectively reduce bone pain and stabilize bone metabolism in patients with metastatic prostate cancer?
Conclusion
Pamidronate may help relieve bone pain and stabilize bone metabolism in some patients with metastatic prostate cancer.
Supporting Evidence
- Eleven of 17 patients with pain at the start of the study were pain free at the end.
- Fasting morning calcium excretion and serum osteocalcin fell significantly with Pamidronate.
- Urine hydroxyproline was lowered in 13 of 20 evaluable patients at 6 months.
- Five of 17 patients with previously progressive bone scans stabilized or regressed on treatment.
Takeaway
This study looked at whether a drug called Pamidronate can help people with prostate cancer feel less pain and keep their bones healthier.
Methodology
Patients received intravenous Pamidronate over 6 months, with pain and metabolic bone activity monitored throughout.
Potential Biases
Potential placebo effects due to the supportive environment of the clinic.
Limitations
The study was preliminary and lacked a control group, making it difficult to draw definitive conclusions.
Participant Demographics
Patients aged 62 to 87 years, mean age 71.3, with hormone-manipulated prostate cancer and bone metastases.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website